Market Introduction
Anaphylaxis is an allergic reaction that can further lead to a fatal condition known as anaphylactic shock. Anaphylaxis occurs when the patient's body reacts to a foreign substance and produces a high amount of histamine that triggers an inflammatory response. It is a severe, life threatening allergic reaction marked by indications such as swallowing and breathing difficulties, skin itching, and lowering blood pressure.
Thus, the rising incidence of anaphylaxis is expected to create a significant demand for anaphylaxis treatment in the coming years, which is further anticipated to drive the anaphylaxis treatment market.
The rapid growth of COVID-19 cases in Europe has had a major impact on the European economy. Spain, Italy, Germany, France, and the United Kingdom are among the European countries most affected. In collaboration with the European Academy of Allergy and Clinical Immunology (EAACI), it published “Allergy and Its Impact on Asthma (ARIA).” Experts in their respective fields recently published a compendium with answers to 150 commonly asked questions about COVID-19 and allergic diseases. Furthermore, readers can put further questions regarding this “living” compendium electronically to the authors, and their answers will be available through a new category in the journal’s webpage. Besides, EAACI, in collaboration with ARIA, has provided recommendations on operational plans and practical procedures for ensuring optimal standards in the daily clinical care of patients with allergic diseases whilst ensuring the safety of patients and healthcare workers. Therefore, growing awareness of allergy linked to COVID-19 in Europe during is likely to demand for anaphyalaxis treatment and supply in COVID Pandemic, hence it can boost the growth of the anaphylaxis treatment market.
Market Overview and Dynamics
The Anaphylaxis treatment market in Europe is expected to grow from US$ 534.0 million in 2021 to US$ 987.2 million by 2028; it is estimated to grow at a CAGR of 9.2% from 2021 to 2028. Cases of allergies have been observed after the COVID-19 vaccination. Along with this, patients with an anaphylaxis history should carry an epinephrine autoinjector to bring it to their vaccination appointment. Along with this initiative, COVID-19 vaccination places should have at least three doses of epinephrine ready at all times, along with the capability to replace supplies after epinephrine is administered to a patient. Nevertheless, anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. These factors present an opportunity for the growth of the anaphylaxis treatment market in the current COVID-19 scenario.
Key Market Segments
In terms of medication type, the epinephrine segment accounted for the largest share of the Europe anaphylaxis treatment market in 2020. In terms of route of administration, the parenteral segment accounted for the largest share of the Europe anaphylaxis treatment market in 2020. In terms of allergy type, the food allergy segment accounted for the largest share of the Europe anaphylaxis treatment market in 2020. In terms of distribution channel, the retail pharmacies segment held a larger market share of the anaphylaxis treatment market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the anaphylaxis treatment market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Amneal Pharmaceuticals Inc., Mylan N.V., BIOPROJET, Abbott, Pfizer Inc., Glaxosmithkline Plc., Merck and Co., Inc., Teva Pharmaceutical Industries Ltd., and ALK-ABELLó.
Reasons to buy report
- To understand the Europe anaphylaxis treatment market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe anaphylaxis treatment market
- Efficiently plan M&A and partnership deals in Europe Anaphylaxis treatment market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe Anaphylaxis treatment market
- Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.
EUROPE ANAPHYLAXIS TREATMENT MARKET SEGMENTATION
By Medication Type
- Epinephrine
- Antihistamines
- Steroids
- Beta-Agonist
- Others
By Route of Administration
- Parenteral
- Oral
- Others
By Allergy Type
- Food Allergy
- Medications
- Insect Stings
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Country
-
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Companies Mentioned
- Amneal Pharmaceuticals Inc.
- Mylan N.V.
- Abbott
- Pfizer Inc.
- Glaxosmithkline Plc.,
- Merck And Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- ALK-ABELLó
- BIOPROJET
Europe Anaphylaxis Treatment Market Strategic Insights
Europe Anaphylaxis Treatment Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 534.0 Million |
| Market Size by 2028 | US$ 987.2 Million |
| CAGR (2021 - 2028) | 9.2% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Medication Type
|
|
Regions and Countries Covered
|
|
| Europe | UK, Germany, France, Russia, Italy, Rest of Europe |
| Market leaders and key company profiles |
|
Europe Anaphylaxis Treatment Market Country and Regional Insights
